Nexentis Technologies Inc. NXTS
Last close
1.72
2026-09-04
Market cap
$2.5M
2026-06-30 share count
52-week range
1.43 - 23.80
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.61
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $210.0K | $263.0K | $394.0K | $438.1K | $232.3K | $175.8K | $426.6K | — |
| Cost of revenue | — | $165.0K | $55.0K | $158.3K | $135.9K | $43.4K | $144.5K | $111.1K | — |
| Gross profit | — | $45.0K | $208.0K | $235.7K | $302.2K | $188.9K | $31.3K | $315.5K | — |
| R&D | $179.0K | $369.0K | $1.9M | $770.8K | $538.7K | $417.0K | $615.6K | $357.1K | — |
| SG&A | $5.1M | $3.3M | $5.6M | $4.7M | $4.3M | $1.1M | $1.0M | $336.4K | — |
| Total operating expenses | — | — | $2.9M | — | — | — | — | — | — |
| Operating income | -$4.2M | -$3.3M | -$7.6M | -$5.8M | -$4.7M | -$1.3M | -$1.9M | -$518.7K | — |
| Interest expense | $0 | $55.0K | $66.0K | $33.7K | — | — | — | — | — |
| Pre-tax income | -$3.6M | -$4.3M | — | — | — | — | — | — | — |
| Income tax | $18.0K | — | — | — | — | — | — | — | — |
| Net income | -$4.0M | -$5.2M | -$6.5M | -$5.7M | -$4.8M | -$1.6M | -$2.0M | -$356.9K | — |
| EPS, basic | -3.54 | -27.74 | -5.43 | 10.85 | -2.06 | — | — | — | — |
| EPS, diluted | -8.61 | -27.74 | -5.43 | 10.85 | -2.06 | -1.05 | -1.38 | -0.05 | — |
| Shares, diluted (wtd. avg.) | 1.3M | 187,215 | 1.2M | 528,776 | 2.3M | 1.5M | 1.4M | 6.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.8M | $1.9M | $4.5M | $5.8M | $6.8M | $242.9K | $290.8K | $439.8K | — |
| Short-term investments | $239.0K | $307.0K | — | — | — | — | — | — | — |
| Receivables | $134.0K | $137.0K | $107.0K | $192.6K | $172.6K | $147.9K | $64.0K | $135.3K | — |
| Inventory | — | $21.0K | $122.0K | $81.7K | $22.6K | $16.4K | $16.3K | $38.1K | — |
| Total current assets | $6.0M | $3.5M | $5.5M | $6.3M | $7.2M | $495.2K | $424.6K | $676.7K | — |
| Property, plant and equipment | $26.0K | $48.0K | $67.0K | $97.9K | $100.9K | $55.2K | $81.1K | $85.1K | — |
| Goodwill | $6.3M | — | — | — | — | — | — | — | — |
| Other intangibles | $4.4M | — | — | — | — | — | — | — | — |
| Total assets | $20.4M | $5.5M | $7.2M | $6.5M | $7.6M | $687.6K | $664.7K | $859.2K | — |
| Accounts payable | $6.0K | $19.0K | $44.0K | $127.5K | $539.4K | $203.3K | $235.9K | $196.6K | — |
| Short-term debt | $1.4M | — | — | — | $8.4K | $7.9K | $7.2K | $22.9K | — |
| Total current liabilities | $1.4M | $892.0K | $779.0K | $714.8K | $931.3K | $785.2K | $623.8K | $483.7K | — |
| Long-term debt | — | — | — | — | $8.4K | $8.1K | $15.0K | $37.9K | — |
| Total liabilities | $4.7M | $892.0K | $786.0K | $754.9K | $1.2M | $1.2M | $1.1M | $647.7K | — |
| Retained earnings | -$38.6M | -$34.6M | -$29.4M | -$22.8M | -$17.1M | -$12.3M | -$10.7M | -$8.7M | — |
| Total equity | $16.0M | $4.7M | $6.5M | $5.7M | $6.4M | -$465.5K | -$402.1K | $211.5K | -$743.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.8M | -$3.4M | -$3.2M | -$5.1M | -$4.1M | -$798.7K | -$1.2M | -$506.5K | — |
| Depreciation and amortisation | $71.0K | $18.0K | $21.0K | $54.7K | $22.0K | $45.2K | $27.4K | $75.6K | — |
| Stock-based compensation | $91.0K | $1.0K | $23.0K | $84.2K | $186.4K | $492.6K | $438.7K | $97.2K | — |
| Capital expenditure | $14.0K | — | — | $51.7K | $67.7K | — | $23.3K | $2.5K | — |
| Investing cash flow | -$3.2M | -$1.9M | -$1.5M | -$51.7K | -$67.7K | -$6.7K | -$81.7K | $5.8K | — |
| Financing cash flow | $8.9M | $3.0M | $3.5M | $4.1M | $10.7M | $741.8K | $1.2M | $912.2K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014183.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Total assets
- R&D
- Goodwill
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | $859.2K | $664.7K | $687.6K | $7.6M | $6.5M | $7.2M | $5.5M | $20.4M |
| R&D | — | $357.1K | $615.6K | $417.0K | $538.7K | $770.8K | $1.9M | $369.0K | $179.0K |
| Goodwill | — | — | — | — | — | — | — | — | $6.3M |
Recent filings and events
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |